Ernexa Therapeutics Inc.
ERNA
$0.2047
-$0.0033-1.59%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -99.79% | 936.17% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -99.79% | 936.17% | |||
| Cost of Revenue | 100.00% | -163.16% | |||
| Gross Profit | -99.82% | 1,239.58% | |||
| SG&A Expenses | -48.77% | -13.22% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -37.58% | -13.18% | |||
| Operating Income | 29.67% | 22.23% | |||
| Income Before Tax | 78.38% | -381.22% | |||
| Income Tax Expenses | -8.33% | 300.00% | |||
| Earnings from Continuing Operations | 78.35% | -381.17% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 78.35% | -381.17% | |||
| EBIT | 29.67% | 22.23% | |||
| EBITDA | 29.49% | 22.28% | |||
| EPS Basic | 96.94% | -380.47% | |||
| Normalized Basic EPS | 83.35% | -2.43% | |||
| EPS Diluted | 96.94% | -380.47% | |||
| Normalized Diluted EPS | 83.35% | -2.43% | |||
| Average Basic Shares Outstanding | 609.02% | 0.00% | |||
| Average Diluted Shares Outstanding | 609.02% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | 1.00% | |||